ReproCell

ReproCell Property, Plant & Equipment

The Property, Plant & Equipment (PP&E) of ReproCell (4978.T) as of Oct 31, 2026 is 101.20 M JPY. In the previous year, Property, Plant & Equipment (PP&E) was 97.00 M JPY — a change of 4.33% (higher).

Property, Plant & Equipment

101.20 MJPY

YoY

4.33%

Last updated:

Property, Plant & Equipment (PP&E) of ReproCell is 2023 101.20 M JPY. Property, Plant & Equipment (PP&E) of ReproCell was 2022 97.00 M JPY. It decreases by 4.33% higher compared to the previous year.

The ReproCell Property, Plant & Equipment history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Property, Plant & Equipment
Date
Property, Plant & Equipment
Jan 1, 2016
61.00 M JPY
Jan 1, 2017
95.00 M JPY
Jan 1, 2018
72.00 M JPY
Jan 1, 2019
178.00 M JPY
Jan 1, 2020
188.00 M JPY
Jan 1, 2021
173.00 M JPY
Jan 1, 2022
97.00 M JPY
Jan 1, 2023
101.20 M JPY
The ReproCell Property, Plant & Equipment history
YEARProperty, Plant & EquipmentYoY
101.20 MJPY+4.33%
97.00 MJPY-43.93%
173.00 MJPY-7.98%
188.00 MJPY+5.62%
178.00 MJPY+147.22%
72.00 MJPY-24.21%
95.00 MJPY+55.74%
61.00 MJPY+27.08%
48.00 MJPY+200.00%
16.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Property, Plant & Equipment (PP&E) of ReproCell is 101.20 M JPY in 2023.

Property, Plant & Equipment (PP&E) of ReproCell changed from 97.00 M JPY to 101.20 M JPY, representing a 4.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Property, Plant & Equipment (PP&E) ReproCell since 2006 – with annual values, charts, and detailed analysis.

PP&E represents the physical assets used in operations, such as buildings, machinery, and equipment. It is the backbone of manufacturing and service delivery.

Property, Plant & Equipment (PP&E)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Property, Plant & Equipment (PP&E)'s ReproCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ReproCell

All Key Metrics — ReproCell